Zydus Lifesciences Ltd - Company Profile
Powered by 
All the sales intelligence you need on Zydus Lifesciences Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Zydus Lifesciences Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Zydus Lifesciences Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zydus Lifesciences Ltd (Zydus Lifesciences) is a life sciences company engaged in the discovery, development, manufacturing, and marketing of healthcare therapies. The company's primary offerings include finished dosage human formulations, such as generics and branded generics, and specialty formulations, such as biosimilars and vaccines, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. The company’s products find application in the therapeutic areas of gastrointestinal, cardiovascular, respiratory, pain management, cancer, inflammation, neurology, and women's health, among others. It has a presence in the US, Europe, South Africa, Japan, Brazil, and other emerging markets. Zydus Lifesciences is headquartered in Ahmedabad, Gujarat, India.
Headquarters
India
Address
Scheme No. 63, Survey No. 536, Zydus Corporate Park, Sarkhej - Gandhinagar Highway, Near Vaishnodevi Circle, Ahmedabad, Gujarat, 382481
Website
www.zyduslife.com
Telephone
91 079 26868100
No of Employees
23,283
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZYDUSLIFE (NSE)
Revenue (2025)
$3.1B
16.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
17.3%
(2025 vs 2024)
Market Cap*
$12.1B
Net Profit Margin (2025)
XYZ
-14.4%
(2025 vs 2024)
* As of and is in US$
Zydus Lifesciences Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Formulations | Lipaglyn |
| Generics Drugs | Bilypsa |
| Generic Biosimilars | Oxemia |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In July, the company signed a partnership with Apollo Hospitals to provide the Shield multi-cancer detection test to patients in India. |
| 2026 | Contracts/Agreements | In May, the company signed an agreement to acquire Assertio for US$166.4 million. |
| 2026 | Regulatory Approval | In April, the company secured approval from DCGI to conduct two Phase III clinical trials of Zintrodiazine. in patients |
Competitor Comparison
| Key Parameters | Zydus Lifesciences Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Ahmedabad | Mumbai | Hyderabad | Mumbai | Mumbai |
| State/Province | Gujarat | Maharashtra | Telangana | Maharashtra | Maharashtra |
| No. of Employees | 23,283 | 43,000 | 27,527 | 31,369 | 19,021 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pankaj R. Patel | Chairman | Executive Board | 2002 | 72 |
| Sharvil P. Patel | Director; Managing Director | Executive Board | - | - |
| Ganesh N. Nayak | Executive Director | Executive Board | 2017 | 70 |
| Vijay Bhalerao | Director - Zydus Healthcare; Director | Executive Board | 2025 | - |
| Swati Dalal | Director - Zydus Healthcare Ltd; Managing Director - Zydus Healthcare Ltd | Executive Board | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer